Veru INC

Veru Inc. has entered into a clinical supply agreement with Novo Nordisk A/S to evaluate enobosarm in combination with Wegovy for obesity in older adults.

Veru Inc. announced fiscal 2026 second quarter financial results, highlighting reduced net loss and progress in its Phase 2b PLATEAU clinical trial for enobosarm.

Veru Inc. shareholders approved an amendment to its 2018 Equity Incentive Plan, significantly increasing the number of shares available for issuance and individual award limits, alongside electing directors and ratifying auditors.

Veru Inc. announced its fiscal 2026 first quarter financial results and provided updates on its enobosarm clinical program for obesity, including plans to initiate the Phase 2b PLATEAU trial.

Veru Inc. announced fiscal year 2025 financial results and significant clinical progress for its enobosarm obesity program, including FDA regulatory clarity and plans for a new Phase 2b study.

Veru Inc. announced the pricing of a public offering of common stock and warrants, expecting to raise $25.2 million in gross proceeds to advance its enobosarm clinical program.

Veru Inc. reports Q2 2026 results, highlighting progress in enobosarm and sabizabulin development, while divesting FC2 business and facing ongoing litigation.

Veru Inc. reported an increased net loss from continuing operations for Q1 2026 but significantly improved its cash position through a public offering, while advancing its enobosarm and sabizabulin drug candidates.

Veru Inc. reports significant net losses and a going concern warning despite positive Phase 2b clinical trial results for enobosarm and strategic pipeline advancements.

Veru Inc. announces positive topline results from its Phase 2b QUALITY clinical study of enobosarm in obese or overweight older patients and provides a financial update in its latest 10-Q filing.

Veru Inc. announces positive Phase 2b clinical trial results for enobosarm in obesity treatment and the sale of its FC2 business, impacting financial results for the quarter ended December 31, 2024.

Veru Inc. announced its Q3 2024 financial results, highlighting a revenue increase and a strategic focus on enobosarm development for obesity and breast cancer.

Veru Inc. reports significant clinical advancements for enobosarm and sabizabulin, alongside substantial net losses and a going concern warning, necessitating further capital.

Veru Inc. reports a net loss for fiscal year 2024 while advancing its enobosarm program for obesity and seeking external funding for sabizabulin.

Veru Inc. has filed an amended annual report to restate its financial statements for fiscal years 2023 and 2022 due to errors in accounting for research and development expenses, also identifying a material weakness in internal controls.

Veru Inc. CEO Mitchell Steiner was granted 604,000 stock options with an exercise price of $2.25 per share.

Veru Inc. Chief Administrative Officer and CFO Michele Greco was granted 164,000 stock options with an exercise price of $2.25.

Veru Inc. Director Loren Katzovitz reported the acquisition of 102,000 stock options with an exercise price of $2.25.

Veru Inc. Director Grace Hyun acquired 97,000 stock options with an exercise price of $2.25.

Veru Inc. Director Michael L. Rankowitz acquired 100,000 stock options with an exercise price of $2.25, vesting over three years.

Veru Inc. director Lucy Lu acquired 104,000 stock options with an exercise price of $2.25, vesting over three years.

Veru Inc. is calling its shareholders to an Annual Meeting on March 12, 2026, to vote on key proposals including the election of directors, auditor ratification, and a significant amendment to its equity incentive plan.

Veru Inc. has announced the engagement of Morrow Sodali LLC as a proxy solicitor for its upcoming Special Meeting of Shareholders on July 25, 2025, at a fee of $12,500 plus expenses.

VERU INC. has filed a definitive proxy statement (DEFA14A) with the SEC, providing information for its upcoming shareholder meeting.

Veru Inc. is seeking shareholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-20 to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement, aiming to avoid delisting and attract broader investor interest.

Veru Inc. has filed a definitive proxy statement with the SEC in accordance with Section 14(a) of the Securities Exchange Act of 1934.

Veru Inc. has scheduled its 2025 Annual Meeting of Shareholders for March 13, 2025, to vote on director elections, auditor ratification, and an equity incentive plan amendment.

BlackRock, Inc. has filed an amendment to its Schedule 13G, disclosing a passive ownership of 1.1% of VERU INC's common stock as of June 30, 2025.

Adage Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 1.57% in Veru Inc.'s common stock as of December 31, 2024.